BenevolentAI is advancing BEN-34712, its experimental oral therapy for amyotrophic lateral sclerosis (ALS), to late-stage preclinical studies. The studies are expected to support a future investigational new drug (IND) application, a formal request to the U.S. Food and Drug Administration (FDA) to test a potential new treatment in clinical…
BenevolentAI candidate BEN-34712 to go to late-stage preclinical studies
About 19 years ago, my newlywed husband, Todd, bought me golf clubs. He loved the sport and thought it’d be a fun way to spend time together. I was open to the idea, even though I used to be one of those kids who dreaded gym class. I’ve never been…
QurAlis soon expects to open its ongoing Phase 1 clinical trial testing QRL-201 in people with amyotrophic lateral sclerosis (ALS) at sites in various European Union countries, including Germany, Belgium, the Netherlands, and Ireland. The company’s announcement comes after these countries reviewed and accepted an application for…
To better understand amyotrophic lateral sclerosis (ALS) and improve patient care, Mitsubishi Tanabe Pharma America (MTPA) is partnering with the ALS/MND Natural History Consortium in collecting real-world data on people with the progressive neurodegenerative disorder. The collaboration will give MTPA access to the consortium’s data repository,…
Last month, a series of health issues bombarded me. They flew in on top of my usual ALS symptoms, causing me to become frustrated and ask, “Has this become my new normal?” But the advice I once received from a TV game show host rescued me — advice that…
Modulo Bio has launched with $8 million in funding and a goal to map the neuroimmune system and develop treatments for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). The neuroimmune system involves interactions between the nervous system and the immune system, which normally protects the nervous system…
Early treatment with ropinirole, a medication used to treat Parkinson’s disease, may slow disease progression in amyotrophic lateral sclerosis (ALS) patients, according to recently published data from a Phase 1/2 trial. Patients given the therapy showed slower functional declines and delayed disease progression over those who started treatment…
Mutations in the KIF5A gene, associated with some cases of amyotrophic lateral sclerosis (ALS), may lead to impairments in motor unit recovery that are exacerbated with age, according to a recent study. Motor units — nerve cells involved in movement and the muscle fibers they interact with — showed poor…
Yes, I know, this headline is an obvious conclusion. Yet, based on my dialogue with other ALS patients, as well as my own experience, it’s not always so obvious. In late 2009, I noticed a drop in my left foot. As it progressed, I asked our family doctor what…
As I fed my husband, Todd, his morning breakfast, a charm of yellow finches caught our attention, flitting to and from a mountain ash outside our dining room window. That old tree has brought many moments of joy that are sweet reprieve from the daily challenges of life with…
Recent Posts
- Dealing with loss, both big and small, in life with ALS
- Scientists use fat-based ‘bubbles’ to sneak ALS treatment into the brain
- Guest Voice: ALS hasn’t stopped this go-to guy from showing up as ‘Dad’
- HEALEY ALS platform trial launches new arm testing oral therapy NUZ-001
- Ahead of this year’s MDA Conference, association’s CEO speaks of ‘hope’